

Edgar Filing: SCHERING PLOUGH CORP - Form 8-K

SCHERING PLOUGH CORP

Form 8-K

May 06, 2004

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

May 3, 2004

Date of Report (Date of Earliest Event Reported)

Schering-Plough Corporation
(Exact name of registrant as specified in its charter)

New Jersey	1-6571	22-1918501
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

2000 Galloping Hill Road
Kenilworth, NJ 07033
(Address of principal executive offices, including Zip Code)

(908) 298-4000
(Registrant's telephone number, including area code)

Item 7. Financial Statements and Exhibits

(c) Exhibit. The following exhibit is filed with this 8-K:

99.1 May 3, 2004 Press Release Titled "Schering-Plough Reaches Agreement With
Texas Attorney General's Office"

Item 9. Regulation FD Disclosure

On May 3, 2004 Schering-Plough announced that it has reached an agreement with

Edgar Filing: SCHERING PLOUGH CORP - Form 8-K

the attorney general's office of the State of Texas to settle issues related to reimbursement by Texas' medicaid program of albuterol sulfate solution and inhaler products. These are asthma products sold by Warrick Pharmaceuticals, Schering-Plough's generic subsidiary. Under the agreement, Schering-Plough has agreed to pay \$27 million to the State of Texas. A press release relating to the settlement is attached to this 8-K as Exhibit 99.2.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Schering-Plough Corporation

By: /s/ Thomas H. Kelly

Thomas H. Kelly
Vice President and Controller

Date: May 5, 2004

Exhibit Index

The following exhibit is filed with this 8-K:

99.1 May 3, 2004 Press Release Titled "Schering-Plough Reaches Agreement With Texas Attorney General's Office"